How big is the U.S. biopharmaceutical CMO & CRO market?

The U.S. biopharmaceutical CMO & CRO market size was estimated at USD 10.1 billion in 2022 and is expected to reach USD 11.1 billion in 2023.

What is the U.S. biopharmaceutical CMO & CRO market growth?

The U.S. biopharmaceutical CMO & CRO market is expected to grow at a compound annual growth rate of 6.1% from 2023 to 2030 to reach USD 16.7 billion by 2030.

Which segment accounted for the largest U.S. biopharmaceutical CMO & CRO market share?

The mammalian segment of the U.S. biopharmaceutical CMO & CRO market held the highest market share of 68.4%. This is attributable to the introduction of novel and robust enhanced expression systems, improved process monitoring solutions, cell line engineering tools, automated screening methods, and disposable devices have all contributed to a more efficient and productive manufacturing process of biologics using mammalian cells.

Who are the key players in U.S. biopharmaceutical CMO & CRO market?

Some key players operating in the U.S. biopharmaceutical CMO & CRO market include Catalent; Lonza Group AG; Boehringer Ingelheim GmbH; Rentschler Biopharma SE; Thermo Fisher Scientific, Inc; AGC Biologics, Fujifilm Diosynth Biotechnologies U.S.A., Inc.; Samsung Biologics; WuXi Biologics, AbbVie Inc., Charles River Laboratories International, Inc., ICON Plc, Parexel International Corporation; Labcorp, Abzena.

What are the factors driving the U.S. biopharmaceutical CMO & CRO market?

Key factors that are driving the biopharmaceutical CMO & CRO market growth include increasing adoption and investment in advanced research and manufacturing technologies by Contract Manufacturing Organizations (CMOs) & Contract Research Organizations (CROs) based in the U.S. is propelling the growth of biopharmaceutical CMO & CRO market in the country. In addition, quality services offered by service providers are driving the biopharma and CMO partnerships in the country.